April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=883 Source: www.ashp.org Tetracycline Capsules March 20, 2012 Products Affected - Description Tetracycline capsules, Teva 250 mg, 100 count (NDC 00172-2416-60) 250 mg, 100 count unit dose (NDC 00172-2416-10) 250 mg, 1000 count (NDC 00172-2416-80) 500 mg, 100 count (NDC 00172-2407-60) 500 mg, 100 count unit dose (00172-2407-10) 500 mg, 1000 count (NDC 00172-2407-80) Tetracycline capsules, Watson 250 mg, 100 count (NDC 00591-2234-01) 250 mg, 1000 count (NDC 00591-2234-10) 500 mg, 100 count (NDC 00591-2235-01) 500 mg, 1000 count (NDC 00591-2235-10) Reason for the Shortage • Teva states tetracycline capsules are unavailable due to a raw material shortage. • Watson could not provide a reason for the shortage but tetracycline capsules have been unavailable since July, 2011. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=816 Source: www.ashp.org Rifampin for Injection March 20, 2012 Products Affected - Description Rifampin for injection, Bedford 600 mg lyophilized vial (NDC 55390-0123-01) Reason for the Shortage • Akorn has sold rifampin to Pfizer who took over the product as of May 1, 2011. • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=350 Source: www.ashp.org Pentostatin Injection March 20, 2012 Products Affected - Description Pentostatin 10 mg powder (NDC 55390-0244-01), Bedford Nipent 10 mg powder (NDC 00409-0801-01), Hospira Reason for the Shortage • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011. Product will become available in stages as production resumes. 48
• Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Hospira states the reason for the shortage is demand exceeding supply due to current market conditions. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=874 Source: www.ashp.org Fentanyl Injection March 20, 2012 Products Affected - Description Fentanyl Injection 50 mcg/mL, Hospira 10 mL ampules (NDC 00409-9093-36) - discontinued 2 mL Carpuject syringe (NDC 00409-1276-32) 2 mL ampule (NDC 00409-9093-32) 5 mL ampule (NDC 00409-9093-35) 20 mL ampule (NDC 00409-9093-38) 2 mL vial (NDC 00409-9094-22) 5 mL vial (NDC 00409-9094-25) 10 mL vial (NDC 00409-9094-28) 20 mL vial (NDC 00409-9094-31) 50 mL vial (NDC 00409-9094-61) Fentanyl Injection 50 mcg/mL, West-Ward (formerly Baxter products) 10 mL ampule (NDC 10019-0034-73) - discontinued 30 mL single-dose vial (NDC 10019-0036-82) - discontinued 2 mL ampule (NDC 10019-0038-67) 20 mL ampule (NDC 10019-0035-74) 2 mL vial (NDC 10019-0037-27) 50 mL vial (NDC 10019-0037-83) 5 mL ampule (NDC 10019-0033-72) 5 mL vial (NDC 10019-0037-30) 20 mL vial (NDC 10019-0037-25) Sublimaze Injection 50 mcg/mL, Akorn 2 mL ampules (NDC 17478-0030-02) 5 mL ampules (NDC 17478-0030-05) 10 mL ampules (NDC 17478-0030-20) Reason for the Shortage • West-Ward acquired Baxter’s fentanyl injection products in May, 2011. The company cannot provide a reason for the shortage. • Hospira states the shortage is due to increased demand and manufacturing delays including quality improvement activities. Hospira is increasing production of the ampules to help meet the demand. • Akorn will be launching Sublimaze injection in late-March, 2012. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=647 Source: www.ashp.org Etoposide Injection March 20, 2012 49
Page 1 and 2: April 2012 Drug Information Update
Page 3 and 4: First-Time Generics GENERIC DRUG NA
Page 5 and 6: GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8: Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10: Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15 and 16: Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47: 750 mg tablets, 100 count (NDC 1013
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68: 2 mL iSecure syringe (NDC 00406-112
Page 69 and 70: Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77 and 78: • Apotex had metformin products u
Page 79: • Covis purchased all rights to F

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?